Abstract:Background:Collagen type X (ColXα1, encoded by COL10A1 ) is expressed specifically in the cartilage-to-bone transition, in bone marrow cells, and in osteoarthritic (OA) cartilage. We have previously shown that ColXα1 is expressed in breast tumor stroma, correlates with tumor-infiltrating lymphocytes, and predicts poor adjuvant therapy outcomes in ER + /HER2 + breast cancer. However, the underlying molecular mechanisms for these effects are unknown. In this study, we performed bioinformatic analysis of COL10A1 -associated gene modules in breast and pancreatic cancer as well as in cells from bone marrow and OA cartilage. These findings provide important insights into the mechanisms of transcriptional and extracellular matrix changes which impact the local stromal microenvironment and tumor progression. Methods:Immunohistochemistry was performed to examine collagen type X expression in solid tumors. WGCNA was used to generate COL10A1 -associated gene networks in breast and pancreatic tumor cohorts using RNA-Seq data from The Cancer Genome Atlas. Computational analysis was employed to assess the impact of these gene networks on development and progression of cancer and OA. Data processing and statistical analysis was performed using R and various publicly-available computational tools. Results:Expression of COL10A1 and its associated gene networks highlights inflammatory and immunosuppressive microenvironments, which identify aggressive breast and pancreatic tumors and contribute to metastatic potential in a sex-dependent manner. Both cancer types are enriched in stroma, and COL10A1 implicates bone marrow-derived fibroblasts as drivers of the epithelial-to-mesenchymal transition (EMT) in these tumors. Heightened expression of COL10A1 and its associated gene networks is correlated with poorer patient outcomes in both breast and pancreatic cancer. Common transcriptional changes and chondrogenic activity are shared between cancer and OA cartilage, suggesting that similar microenvironmental alterations may underlie both diseases. Conclusions:COL10A1 -associated gene networks may hold substantial value as regulators and biomarkers of aggressive tumor phenotypes with implications for therapy development and clinical outcomes. Identification of tumors which exhibit high expression of COL10A1 and its associated genes may reveal the presence of bone marrow-derived stromal microenvironments with heightened EMT capacity and metastatic potential. Our analysis may enable more effective risk assessment and more precise treatment of patients with breast and pancreatic cancer. Research Highlights:ColX highlights features of EMT in breast and pancreatic cancerColX gene modules are immunosuppressive and pro-metastaticColX-associated gene networks contribute to sex differences in pancreatic cancerColX-positive fibroblasts define more aggressive tumors with poorer survivalColX is emerging as a biomarker for bone marrow-derived cells in cancer.

COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer

Integrated Bioinformatics Analysis Identified COL11A1 As an Immune Infiltrates Correlated Prognosticator in Pancreatic Adenocarcinoma

COL11A1 Serves As a Biomarker for Poor Prognosis and Correlates with Immune Infiltration in Breast Cancer

Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor‐infiltrating immune cells in ovarian cancer

COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells

COL12A1, a Novel Potential Prognostic Factor and Therapeutic Target in Gastric Cancer.

Microenvironment Remodeled by Tumor and Stromal Cells Elevates Fibroblast-Derived COL1A1 and Facilitates Ovarian Cancer Metastasis.

Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment

High expression of COL10A1 is associated with poor prognosis in colorectal cancer.

COL5A1 Overexpression Correlates with Poor Prognosis in Human Cervical Cancer

Bioinformatics Analysis of Prognostic Significance of COL10A1 in Breast Cancer.

Collagen type 1 alpha 1 chain is a novel predictive biomarker of poor progression-free survival and chemoresistance in metastatic lung cancer

Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target.

Upregulation of COL6A1 is Predictive of Poor Prognosis in Clear Cell Renal Cell Carcinoma Patients

Bioinformatics analysis and experimental validation of the oncogenic role of COL11A1 in pan-cancer

The Hypoxia-Related Gene COL5A1 is a Prognostic and Immunological Biomarker for Multiple Human Tumors.

COL11A1 promotes esophageal squamous cell carcinoma proliferation and metastasis and is inversely regulated by miR-335-5p

Overexpression of COL11A1 confers tamoxifen resistance in breast cancer

COL1A1: A novel oncogenic gene and therapeutic target in malignancies

High Expression of COL10A1 Is an Independent Predictive Poor Prognostic Biomarker and Associated with Immune Infiltration in Advanced Gastric Cancer Microenvironment

Aberrant Expression of Collagen Type X in Solid Tumor Stroma is Associated with EMT, Immunosuppressive and Pro-Metastatic Pathways, Bone Marrow Stromal Cell Signatures, and Poor Survival Prognosis